Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) presented four groundbreaking studies at the 85th Annual American Diabetes Association Scientific Sessions, showcasing significant achievements in GLP-1 medication management and AI-powered personalization.

A landmark study of 715 GLP-1 users demonstrated remarkable improvements, with average blood glucose dropping from eA1c of 9.0% to 6.7%. Notably, patients maintained stable outcomes for six months after discontinuing GLP-1 medication, showing no significant weight or glucose rebound.

The company's AI research achieved 89% accuracy in predicting next-month blood glucose levels using machine learning models. The studies revealed that the first four months of engagement are crucial for personalized care, with older adults (60+) showing stronger sustained outcomes.

Positive

• Blood glucose reduction from eA1c 9.0% to 6.7% in GLP-1 users
• Sustained outcomes for 6 months post-GLP-1 discontinuation with no significant rebound
• 89% accuracy in AI blood glucose prediction
• Platform demonstrates ability to maximize ROI for costly GLP-1 programs
• Strong clinical validation with 25 published studies at ADA Scientific Sessions

Negative

• None.

Insights

Medical Technology Analyst

Dario's research shows sustained post-GLP-1 outcomes and 89% accurate AI glucose prediction, positioning them strongly in the competitive digital health market.

Dario's latest research demonstrates a significant clinical advancement in two critical healthcare areas: GLP-1 therapy sustainability and AI-powered glucose management. The landmark study of 715 GLP-1 users revealed that patients maintained stable outcomes for six months after discontinuing medication - addressing one of the biggest challenges in the GLP-1 market where rebound effects typically occur. This is evidenced by the dramatic eA1c reduction from 9.0% to 6.7% in users.

The AI research findings are equally compelling. Dario's machine learning model achieved 89% accuracy in predicting next-month blood glucose levels using behavioral and activity data - not just clinical measurements. This represents a meaningful advance in personalized digital therapeutics, particularly as the research identified that the first four months of engagement are crucial for establishing self-care behaviors.

What makes these findings commercially significant is their direct application to the explosive GLP-1 market. With medications like Ozempic and Wegovy costing upwards of $1,000 monthly, payers and employers are desperately seeking solutions to maximize ROI on these expensive therapies. Dario's platform potentially addresses this by demonstrating that digital engagement can sustain outcomes beyond medication use, potentially reducing long-term costs.

The age-specific findings also reveal an often-overlooked opportunity: older adults (60+) showed stronger and more sustained outcomes with greater participation in lifestyle activities. This suggests Dario could target demographic-specific interventions, expanding their addressable market.

These studies represent Dario's 25th published research at ADA over a decade, reflecting consistent scientific investment. More importantly, the company explicitly states they're leveraging these findings in commercial discussions, indicating potential revenue acceleration in the near term.

Dario's new research shows sustained outcomes post-GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to leverage these findings in commercial discussions

NEW YORK, June 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced four new studies presented this past weekend at the 85th Annual American Diabetes Association ("ADA") Scientific Sessions in Chicago. The research, which represents Dario's 25th published study at the ADA's Scientific Sessions over the last decade, includes groundbreaking findings in sustaining GLP-1 weight loss and artificial intelligence ("AI")-powered personalization that highlight the Company's platform's critical contribution in the digital health market.

 

Key highlights from the research include a dramatic eA1c reduction from 9.0% to 6.7% in GLP-1 users, with users seeing sustained results for six (6) months after medication discontinuation, and AI predictive accuracy of 89% for future glucose levels, demonstrating Dario's unique position to deliver value in the GLP-1 market where payers and employers seek solutions that maximize their investment in these costly medications.

The Company is currently leveraging these findings in ongoing implementations and commercial discussions with payers and self-insured employers seeking integrated solutions for chronic condition management, particularly around GLP-1 optimization programs.

Landmark GLP-1 Study Demonstrates Sustainable Results Beyond Medication

The first study examined 715 GLP-1 users and revealed significant clinical improvements for those engaging with Dario's platform. Most importantly, the research showed that users who discontinued GLP-1 medication maintained stable outcomes, reflecting no significant weight or glucose rebound, for at least six (6) months, addressing a critical industry challenge where patients typically experience rebound effects after stopping treatment.

 Key study results included:

• Among continued GLP-1 users with elevated glucose levels, average blood glucose dropped from an eA1c of 9.0% to 6.7%.
• Digital lifestyle engagement activities significantly enhanced outcomes with meal and physical activity logging associated with stronger blood glucose improvements.
  • Weight logging and educational content were linked to greater weight reduction.
• Members who discontinued GLP-1s experienced no significant weight or glucose rebound over six (6) months, with outcomes remaining statistically equivalent to those who continued medication.

These findings underscore the importance of integrated digital tools in supporting medication adherence, optimizing outcomes, and sustaining progress even after GLP-1 treatment ends.

"We believe that this research validates our approach to the GLP-1 market," said Omar Manejwala, M.D., Chief Medical Officer at Dario. "By demonstrating that our platform sustains outcomes beyond medication use, we believe that we are providing a solution that helps members while maximizing return on investment for health plans and employers implementing costly GLP-1 programs."

AI Research Advances Personalization in Digital Health

Three additional studies published at the ADA conference offer insights on the potential of AI and real-world data to drive more personalized, effective chronic condition management. The studies reflect early research fueling Dario's next-generation AI platform, which leverages machine learning to tailor interventions based on real-time behaviors, clinical biomarkers, and user demographics.

Key results from the studies include:

• 89% accuracy in predicting next-month blood glucose levels using a machine learning model informed by user behavior and activity—not just clinical data.
• Machine learning revealed that the first four months of engagement and consistent self-care behaviors are key opportunities to apply AI for more personalized, adaptive diabetes care to improve outcomes.
• Age proved to be the most significant moderator of results in members with diabetes, with older adults (60+) showed stronger and more sustained outcomes with greater participation in lifestyle activities, highlighting the opportunity for age-tailored personalization.

These results showcase how Dario is using AI to turn data into dynamic care pathways, helping people achieve better outcomes through smarter, more personalized digital health experiences.

"We believe that our AI research can directly translate to commercial value," said Yifat Hershcovitz, PhD, Vice President of Clinical and Scientific Affairs at Dario. "As we implement these insights with our enterprise clients, we're delivering more personalized, effective solutions that have the potential to drive both clinical outcomes and business results."

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. 

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the Company's ability to leverage the new research findings in commercial discussions; that the Company's platform can sustain outcomes beyond medication use; that the Company's solutions will maximize return on investment for health plans and employers implementing costly GLP-1 programs; the belief that the Company's AI research will translate to commercial value; and that the Company's solutions have the potential to drive both clinical outcomes and business results. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:
Mary Mooney
VP Marketing
+1-312-593-4280

DarioHealth Investor Relations Contact:
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922

Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/dario-unveils-groundbreaking-glp-1-and-ai-personalization-digital-health-findings-302489404.html

SOURCE DarioHealth Corp.

FAQ

What were the key findings of DarioHealth's (DRIO) GLP-1 study in 2025?

The study of 715 GLP-1 users showed blood glucose reduction from eA1c 9.0% to 6.7%, and importantly, users maintained stable outcomes with no significant weight or glucose rebound for 6 months after discontinuing medication.

How accurate is DarioHealth's AI blood glucose prediction system?

DarioHealth's machine learning model achieved 89% accuracy in predicting next-month blood glucose levels, using both user behavior and activity data.

What is the significance of DarioHealth's GLP-1 research for healthcare payers?

The research demonstrates that Dario's platform can help maximize return on investment for health plans and employers implementing costly GLP-1 programs by maintaining positive outcomes even after medication discontinuation.

How does age affect outcomes in DarioHealth's platform users?

The research showed that age is the most significant moderator of results, with adults over 60 demonstrating stronger and more sustained outcomes when participating in lifestyle activities.

What role does digital engagement play in DarioHealth's GLP-1 outcomes?

Digital lifestyle engagement, including meal and physical activity logging, significantly enhanced outcomes, while weight logging and educational content were linked to greater weight reduction.